MedTrace Logo

Intravitreal Bevacizumab for Diabetic Retinopathy

NCT00600262 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2024-05-30

No results posted yet for this study

Summary

Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas and regression of retinal and disc neovasculrization.

Methods: 40 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity, neovascularization leakage points, capillary closure ischemic areas and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.

Conditions

  • Severe Nonproliferative
  • Proliferative Diabetic Retinopathy
  • Active Photocoagulated Diabetic Retinopathy

Interventions

DRUG

intravitreal bevacizumab

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Elizabeth Reyna-Castelan, MD · Asociación para evitar la ceguera en Mexico

  • Mariana Martinez-Castellanos, MD · Asociación para Evitar la Ceguera en México

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2006-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600262 on ClinicalTrials.gov